What are the indications for intranasal desmopressin?

Indications for Intranasal Desmopressin

Intranasal desmopressin should NOT be used for nocturnal enuresis due to increased risk of hyponatremia and water intoxication, and oral formulations are strongly preferred for all antidiuretic indications. 1

Current FDA-Approved Indications

Intranasal desmopressin remains indicated for:

Central Cranial Diabetes Insipidus

• Primary indication for patients with confirmed AVP deficiency requiring antidiuretic therapy 2
• Critical caveat: Should NOT be used if nasal mucosa changes exist (scarring, edema, disease) causing erratic absorption—switch to injectable formulation 1
• Dosing: 10-40 mcg nightly (1-4 sprays) 3

Hemostatic Indications

• Von Willebrand disease (first-line treatment) 4, 5
• Mild hemophilia A 5
• Platelet dysfunction in trauma/bleeding scenarios, particularly:
  • Patients on antiplatelet agents (aspirin, clopidogrel) with active bleeding 4, 6
  • Uremia-related platelet dysfunction 5
  • Congenital platelet function defects 5
• Standard hemostatic dose: 0.3 mcg/kg diluted in 50 mL saline over 30 minutes 4

Contraindications to Intranasal Formulation

Absolute contraindications 2:

• Moderate to severe renal impairment (CrCl <50 mL/min)
• Hyponatremia or history of hyponatremia
• Known hypersensitivity to desmopressin

Relative contraindications 2:

• Polydipsia (excessive fluid intake)
• Cystic fibrosis
• Heart failure
• Conditions with fluid/electrolyte imbalance

Critical Safety Considerations

Why Intranasal is Discouraged for Enuresis

The enuresis indication has been removed for nasal spray in many countries 1 because:

1. Higher hyponatremia risk: All 48 published case reports of hyponatremia in children with enuresis involved intranasal formulation 7
2. Post-marketing data: Of 151 hyponatremia cases in children with enuresis, 145 (96%) used intranasal vs. only 6 (4%) used oral formulation 7
3. Erratic absorption: Uncertain ability of children to effectively administer nasal spray; nasal congestion/sinusitis impairs absorption 3

Hyponatremia Risk Factors

• Extremes of age (especially <6 years) 8, 7
• Intranasal formulation 1, 8, 7
• Excessive fluid intake 1, 2
• Drug interactions: Tricyclics, SSRIs, NSAIDs, carbamazepine, lamotrigine 2
• Intercurrent illness affecting hydration 3

Prodromal Symptoms of Water Intoxication

Patients must be instructed to immediately discontinue and seek assessment if experiencing 2, 7:

• Headache
• Nausea
• Vomiting

Practical Prescribing Algorithm

For Central Diabetes Insipidus:

1. Confirm intact nasal mucosa (no scarring, edema, disease)
2. If nasal mucosa compromised → use injectable formulation
3. If nasal mucosa intact → may use intranasal 10-40 mcg nightly
4. Monitor urine volume/osmolality; plasma osmolality if needed 2

For Hemostatic Indications:

1. Confirm diagnosis (von Willebrand disease, mild hemophilia A, or documented platelet dysfunction)
2. Administer 0.3 mcg/kg IV over 30 minutes (intranasal less reliable for acute bleeding)
3. Consider platelet function testing (PFA-100, multiple electrode aggregometry) to identify responders 4

For ANY Indication:

• Restrict evening fluid intake to ≤200 mL (6 oz) when using for antidiuretic effect 1
• Avoid in patients with polydipsia
• Monitor electrolytes if intercurrent illness develops 3
• Use oral formulations preferentially when available 1

Formulation Preference Hierarchy

1. Oral tablet or lyophilisate: Preferred for all antidiuretic indications due to superior safety profile 1, 8
2. Injectable: For acute hemostatic needs or when nasal absorption unreliable 1, 4
3. Intranasal: Reserved only for central diabetes insipidus with intact nasal mucosa when other formulations unavailable 1, 2